Special Issue

Design, Synthesis, Evaluation and Biopharmaceutical Uses of Imatinib, Nilotinib and Their Analogues

Message from the Guest Editors

In 2001, a revolutionary drug, which turned out to be very effective for the treatment of chronic myeloid leukemia (CML), was approved and released, changing the approach of cancer's target therapy. The active substance, named Imatinib, was designed to deactivate a specific protein kinase, a fused BCR-ABL tyrosine protein kinase, terminating the cell signaling pathway that was responsible for the uncontrolled proliferation of white blood cells. With Imatinib as the starting point, the innovative approach of blocking problematic protein kinase with low-molecular-weight molecules, usually by binding with the ATP-binding sites, led to the synthesis of a series of protein kinase inhibitors. We focuses on state-of-the-art research works related to the following:

- The design of new synthetic approaches of Imatinib and Nilotinib:
- The development of their novel analogues;
- The evaluation of their biological properties and selectivity;
- Their biopharmaceutical uses.

We invite you to submit your original research articles for publication in this Special Issue.

Guest Editors

Dr. Dimitrios Alivertis

Prof. Dr. Alexandros D. Tselepis

Dr. Pinelopi Voulgari

Deadline for manuscript submissions

closed (25 March 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/195809

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

